التفاصيل البيبلوغرافية
| العنوان: |
A neutrophilic dermatosis following treatment of myelofibrosis with ruxolitinib: An emerging phenomenon? |
| المؤلفون: |
Jiang, Melinda, Tran, Alain Khoi, Marshman, Gillian |
| المصدر: |
Australasian Journal of Dermatology; Nov2021, Vol. 62 Issue 4, pe607-e609, 3p, 3 Color Photographs, 1 Chart |
| مصطلحات موضوعية: |
SWEET'S syndrome, RUXOLITINIB, MYELOFIBROSIS, PROTEIN-tyrosine kinase inhibitors, SYMPTOMS, GRANULOCYTE-colony stimulating factor |
| مستخلص: |
Neutrophilic dermatosis, pyoderma gangrenosum, tyrosine kinase inhibitor, pathergy, ruxolitinib, sweet syndrome Moreover, this case demonstrated a convincing temporal relationship with lesions appearing five weeks after commencing tyrosine kinase inhibitor therapy; this aligns well with the median two-month latency time reported in the literature. Keywords: neutrophilic dermatosis; pathergy; pyoderma gangrenosum; ruxolitinib; sweet syndrome; tyrosine kinase inhibitor EN neutrophilic dermatosis pathergy pyoderma gangrenosum ruxolitinib sweet syndrome tyrosine kinase inhibitor e607 e609 3 11/23/21 20211101 NES 211101 Ruxolitinib is a Janus kinase (JAK) inhibitor used in the treatment of myelofibrosis. [Extracted from the article] |
|
Copyright of Australasian Journal of Dermatology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder